

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CHINA ISOTOPE & RADIATION CORPORATION

中國同輻股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

VOLUNTARY ANNOUNCEMENT

CNNC ACCURAY'S NATIONAL HIGH-END TOMOTHERAPY SYSTEM (TOMO C) PROJECT SUCCESSFULLY OBTAINED THE MEDICAL DEVICE REGISTRATION CERTIFICATE AND THE MEDICAL DEVICE MANUFACTURING LICENSE

This announcement is made on a voluntary basis by China Isotope & Radiation Corporation (the “**Company**”) to keep shareholders and potential investors informed of the latest business developments of the Company.

The board of directors (the “**Board**”) of the Company is pleased to announce that, recently, CNNC Accuray (Tianjin) Medical Technology Co., Ltd. (中核安科銳(天津)醫療科技有限責任公司) (“**CNNC Accuray**”) has successfully obtained the medical device registration certificate and the medical device manufacturing license issued by the National Medical Products Administration (NMPA) for CNNC Accuray's domestic high-end TomoTherapy system (Tomo C) project. This product is characterised with advanced KV and MV double-helix CT image guidance, first-class treatment accuracy, intelligent dose algorithm, and simple software process, which will provide more accurate radiotherapy for clinical use, and assist doctors in providing patients with more excellent tumor radiation treatment options and better medical services.

CNNC Accuray was established on 26 March 2019 as a sino-foreign joint venture, which was contributed as to 51% and 49% by CNNC High Energy Equipment (Tianjin) Co., Ltd. (中核高能(天津)裝備有限公司), a wholly-owned subsidiary of the Company, and Accuray Asia Ltd (安科銳亞洲有限公司), respectively. The company owns two high-end radiotherapy platforms, namely the TomoTherapy system (Tomo) and the X-ray Stereotactic Radiotherapy system (Cyber Knife), which are equipped in radiotherapy or oncology departments of hospitals and mainly used to implement image-guided intensity modulated radiotherapy and stereotactic radiotherapy for tumors and other lesions throughout the body.

CNNC Accuray will adhere to the philosophy of “In China, For China”, so that more tumor patients in China can have access to high-quality radiotherapy equipment and will promote the localisation and popularisation of high-end radiotherapy equipment to benefit more tumor patients in the future.

By order of the Board
China Isotope & Radiation Corporation
Wang Suohui
Chairman

Beijing, the PRC, 28 September 2023

As at the date of this announcement, the Board comprises Mr. Wang Suohui, Mr. Xu Hongchao and Mr. Du Jin as executive Directors; Mr. Chen Shoulei, Mr. Ding Jianmin, Ms. Chang Jinyu and Ms. Liu Xiuhong as non-executive Directors; and Mr. Poon Chiu Kwok, Mr. Tian Jiahe, Ms. Chen Jingshan and Mr. Lu Chuang as independent non-executive Directors.